Pharm Exec Podcast

Cameron Turtle, Chief Business Officer of Eidos Therapeutics, Robin Toft, Founder and CEO of The Toft Group Executive Search and Sabrina Johnson, President and CEO, Daré Bioscience join Pharm Exec editors to talk about the future of the life sciences executive.

Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.

Pharm Exec's European Editor, Julian Upton, speaks with Johnson & Johnson's Jennifer Turgiss, VP Behavior Science & Advanced Analytics group. In their interview, Turgiss discusses behavioral strategies to the health and wellness solutions being developed at J&J.

Editor-in-Chief Lisa Henderson speaks with Bill Newell, CEO of Sutro Biopharma about his background in corporate law and how it helps him in his role as a biotech executive, the importance of collaboration between big pharma and biotech, a story about keeping the San Francisco Giants in the Bay area, and other analogies around sports related to running a biotech.

Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease. This podcast was brought to you by QxMD.

Pharm Exec's European Editor, Julian Upton, caught up with Ben Wiegand, head of J&J's World Without Disease Accelerator unit, at eyeforpharma Barcelona. They talk about Wiegand's panel "Uniting Patients, Providers, and Payers to Bring Preventative Care to Life," and J&J's disease prevention and interception activities. This podcast was brought to you by QxMD.

Michelle Maskaly and Christen Harm speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.

Pharm Exec editors talk with Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals about how to navigate creating drugs for conditions such as PTSD and AIDS, running a business, and academia.

Pharm Exec editors sit down with Bob Ward, chairman and CEO of Eloxx Pharmaceuticals, to talk about his personal, as well as Eloxx’s, commitment to working with patient advocacy groups, how to attract talent, and how to put together a great team.

Michelle Maskaly and Christen Harm talk with David Shao, CEO of Yisheng Biopharma, about what’s driving China’s exploding pharma and biotech industries, as well as the country’s push to become a global life science leader.

Michelle Maskaly and Christen Harm sit down with Editor-in-Chief Lisa Henderson and European Editor Julian Upton to discuss the industry trends featured in Pharm Exec's January 2019 issue.

Pharm Exec editors Michelle Maskaly and Christen Harm speak with Raymond Sanchez, senior vice president of Global Clinical Development at Otsuka Pharmaceutical Development & Commercialization. Raymond talks about his switch from academia to clinical development, the sobering affect of seeing a drug he helped develop on the pharmacy shelf, and how he uses mindfulness to encourage and lead his team.

Nicola Kayel, Vice President of Marketing at Salix Pharmaceuticals, speaks with Pharm Exec editors about the challenges and strategies for marketing drugs that treat embarrassing conditions, like irritable bowel syndrome. She also discusses the company's recent plunge into virtual and augmented reality and how it plays a role in the future for healthcare professionals.

Jack Bailey, president of US pharmaceuticals for GlaxoSmithKline, talks with Christen Harm and Michelle Maskaly, about the biopharma landscape in the southeastern part of the United States, as part of Pharm Exec’s ongoing series that looks at growing biotech innovation hubs across the country. Bailey gives unmatched insights about the efforts North Carolina has put into growing, attracting, and retaining life science startups, specifically in the Raleigh-Durham area, as well as addresses challenges such as access to venture capital.

Pharm Exec Editorial Director Lisa Henderson and European Editor Julian Upton talk with Michelle Maskaly and Christen Harm about the magazine’s recent pharmaceutical pipeline report which was published in the November 2018 issue. Topics include cannabis, CAR-T therapy, opioids, biosimilars, and Alzheimer’s.

Christen and Michelle talk with Mei Mei Hu, CEO of United Neuroscience, about how being open to pivoting from your original plan can create a number of opportunities for an executive and their company, as well as how her executive team successfully manages a remote workforce spread across three continents. In a hilarious conversation about balancing professional and personal life, Hu also talks about how she ended up leading a spinout of her family’s life sciences business after a career in consulting, despite vowing to never be a part of the biotech world.

Michelle and Christen sit down with one of this year's Emerging Pharma Leaders, Christopher Boone, the head of real-world data and analytics center of excellence at Pfizer. We discuss what peaked Boone's interest in public health and data; the progression of how pharma and data have merged; what challenges pharma faces with data and what lies ahead; and where he got his infamous twitter handle.

On Target Laboratories, CEO and Co-Founder, Martin R. Low and Philip S. Low, whose work the company is based off of and is also a co-founder of the company, join Christen Harm and Michelle Maskaly to talk about the ups and downs of commercializing research that has been previously shelved. They share how they approached another company to license the technology, why being persistent is a good thing if you truly believe the research can make a difference in the lives of patients, and talk about what it’s been like to work with each other in a business, given that they are brothers. Martin R. Low also discusses what it’s been like for him to run a pharma company, since his prior expertise ranges a variety of other industries outside of pharma.

Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.

Learn how pharma companies are using robotics and artificial intelligence when it comes to patient care, what the funding landscape is for businesses in this sector, and as a member of the c-suite find out what you need to do now to be at the forefront of this emerging technology.